Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of INT-2150 in Healthy Males
NCT03509831Phase 1Unknown
- Sponsor
- Kukje Pharm
- Start
- Nov 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of INT-2150 in gastritis (2 arms), sponsored by Kukje Pharm. Primary endpoints: Area Under the Curve to the last measurable concentration and Maximum Plasma Concentration. Status: unknown.
02
Drugs
INT-2150
03
Conditions
gastritis
Beyond the preview
Go deeper on NCT03509831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03509831.